McMillion Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

McMillion Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-216	Closed	-$30K	–	291
2020 Q4	$30K	Buy	+216	New	+$27.7K	0.02%	142
2020 Q2	–	Sell	-216	Closed	-$17K	–	282
2020 Q1	$17K	Hold	216	–	–	0.01%	144
2019 Q4	$21K	Hold	216	–	–	0.01%	158
2019 Q3	$16K	Hold	216	–	–	0.01%	166
2019 Q2	$19K	Buy	+216	New	+$18.4K	0.01%	161

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

McMillion Capital Management's XBI Position: Q1 2021 in Review

McMillion Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2021, closing a stake of 216 shares — an estimated $30K sold.

McMillion Capital Management first reported a position in XBI in Q2 2019 and held it in 5 quarters. The position peaked at $30K in Q4 2020. 643 funds tracked by Wall St. Rank hold XBI as of Q1 2021.

McMillion Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2021 after selling out during the quarter.
McMillion Capital Management sold 216 State Street SPDR S&P Biotech ETF shares in Q1 2021, an estimated $30K.
McMillion Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2019 and held it in 5 quarters.
McMillion Capital Management's State Street SPDR S&P Biotech ETF position peaked at $30K in Q4 2020.
643 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2021.

Based on McMillion Capital Management's 13F filing for Q1 2021, filed 13 May 2021.